HUTCHMED (China) 주식 주식분석 | 주식가격 | 뉴스 | 13.HK | KYG4672N1198 | A2PJ5B

날짜	HUTCHMED (China) 주식 가격
	0.36 undefined
	0.37 undefined
	0.37 undefined
	0.37 undefined
	0.38 undefined
	0.38 undefined
	0.40 undefined
	0.39 undefined
	0.41 undefined
	0.41 undefined
	0.40 undefined
	0.40 undefined
	0.40 undefined
	0.40 undefined
	0.37 undefined
	0.37 undefined
	0.38 undefined
	0.39 undefined
	0.36 undefined
	0.37 undefined
	0.37 undefined

날짜	HUTCHMED (China) 매출	HUTCHMED (China) EBIT	HUTCHMED (China) 이익
2029e	1.74 조. undefined	0 undefined	0 undefined
2028e	1.55 조. undefined	383.41 백만 undefined	0 undefined
2027e	1.33 조. undefined	220.36 백만 undefined	229.31 백만 undefined
2026e	1.02 조. undefined	50.26 백만 undefined	122.13 백만 undefined
2025e	847.53 백만 undefined	-34.47 백만 undefined	37.04 백만 undefined
2024e	697.44 백만 undefined	-140.98 백만 undefined	-98.85 백만 undefined
2023	838 백만 undefined	18.38 백만 undefined	100.78 백만 undefined
2022	426.41 백만 undefined	-407.69 백만 undefined	-360.84 백만 undefined
2021	356.13 백만 undefined	-328.32 백만 undefined	-194.65 백만 undefined
2020	227.98 백만 undefined	-196.67 백만 undefined	-125.73 백만 undefined
2019	204.89 백만 undefined	-146.39 백만 undefined	-106.02 백만 undefined
2018	214.11 백만 undefined	-92.64 백만 undefined	-74.81 백만 undefined
2017	241.2 백만 undefined	-53.42 백만 undefined	-26.74 백만 undefined
2016	216.08 백만 undefined	-46.7 백만 undefined	11.7 백만 undefined
2015	178.2 백만 undefined	-9.77 백만 undefined	-35.01 백만 undefined
2014	87.33 백만 undefined	-18.26 백만 undefined	-32.82 백만 undefined
2013	46 백만 undefined	-1 백만 undefined	5.9 백만 undefined
2012	195.4 백만 undefined	-1.3 백만 undefined	3.6 백만 undefined
2011	166.9 백만 undefined	5.2 백만 undefined	700,000 undefined
2010	134.5 백만 undefined	-3.1 백만 undefined	-6.9 백만 undefined
2009	111 백만 undefined	-5.6 백만 undefined	-8.7 백만 undefined
2008	87 백만 undefined	-15.4 백만 undefined	-17.8 백만 undefined
2007	65.1 백만 undefined	-9.7 백만 undefined	-17.2 백만 undefined
2006	57.5 백만 undefined	-8.2 백만 undefined	-9.6 백만 undefined
2005	37.9 백만 undefined	-6.2 백만 undefined	-6.8 백만 undefined
2004	17.5 백만 undefined	-5.3 백만 undefined	-6.7 백만 undefined

	매출	EBIT	이익
2004	17.5 백만 USD	-5.3 백만 USD	-6.7 백만 USD
2005	37.9 백만 USD	-6.2 백만 USD	-6.8 백만 USD
2006	57.5 백만 USD	-8.2 백만 USD	-9.6 백만 USD
2007	65.1 백만 USD	-9.7 백만 USD	-17.2 백만 USD
2008	87 백만 USD	-15.4 백만 USD	-17.8 백만 USD
2009	111 백만 USD	-5.6 백만 USD	-8.7 백만 USD
2010	134.5 백만 USD	-3.1 백만 USD	-6.9 백만 USD
2011	166.9 백만 USD	5.2 백만 USD	700,000 USD
2012	195.4 백만 USD	-1.3 백만 USD	3.6 백만 USD
2013	46 백만 USD	-1 백만 USD	5.9 백만 USD
2014	87.33 백만 USD	-18.26 백만 USD	-32.82 백만 USD
2015	178.2 백만 USD	-9.77 백만 USD	-35.01 백만 USD
2016	216.08 백만 USD	-46.7 백만 USD	11.7 백만 USD
2017	241.2 백만 USD	-53.42 백만 USD	-26.74 백만 USD
2018	214.11 백만 USD	-92.64 백만 USD	-74.81 백만 USD
2019	204.89 백만 USD	-146.39 백만 USD	-106.02 백만 USD
2020	227.98 백만 USD	-196.67 백만 USD	-125.73 백만 USD
2021	356.13 백만 USD	-328.32 백만 USD	-194.65 백만 USD
2022	426.41 백만 USD	-407.69 백만 USD	-360.84 백만 USD
2023	838 백만 USD	18.38 백만 USD	100.78 백만 USD
2024e	697.44 백만 USD	-140.98 백만 USD	-98.85 백만 USD
2025e	847.53 백만 USD	-34.47 백만 USD	37.04 백만 USD
2026e	1.02 조. USD	50.26 백만 USD	122.13 백만 USD
2027e	1.33 조. USD	220.36 백만 USD	229.31 백만 USD
2028e	1.55 조. USD	383.41 백만 USD	0 USD
2029e	1.74 조. USD	0 USD	0 USD

2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022

0	0.02	0.01	0.07	0.05	0.04	0.04	0.05	0.05	0.06	0.05	0.05	0.03	0.1	0.36	0.3	0.22	0.44	1.01	0.63
4.8	5.5	12.9	16.6	21.2	22.4	20.1	30.7	51.6	44.3	13.4	34.4	35.22	45.04	42.27	42.96	43.25	46.93	82.41	97.99
0.1	1.2	1.5	0	0	0	0	0	1.5	15	2	1.6	11.06	4.13	16.34	14.32	35.73	19.99	66.82	30.67
2.3	2.7	8.7	9.5	11.7	14.7	17.5	26.6	28.7	25.3	1.4	4.4	9.56	12.82	11.79	12.31	16.21	19.77	35.76	56.69
1.4	0.2	1.3	2.1	2.2	2.6	4.6	5.1	5.1	3.9	3.4	2.6	1.43	1.07	2.57	0	3.77	7.04	14.13	22.33
0.01	0.03	0.03	0.1	0.09	0.08	0.08	0.11	0.14	0.15	0.07	0.09	0.09	0.17	0.43	0.37	0.32	0.53	1.21	0.84
11.7	13.3	22	22.9	25.7	32	30.7	29.9	29.5	33.3	6.5	8.9	9.85	11.17	15.48	17.79	27.48	32.19	53.15	84.67
0.8	0.7	0	0.1	0.1	0.1	0.1	0	0	0	111.4	113	119.76	158.51	144.24	138.32	98.94	139.51	76.48	73.78
0	0	0	0	0	0	0	3	0	0	0	0	0	0	0	0	16.19	0	0	0
2.9	1	0.9	5	6.4	0.5	5	10.3	14.9	15.6	0	0.7	0.57	0.47	0.43	0.35	0.28	0	0	0
2.4	2.4	5.9	6.2	6.6	7.1	7.5	7.7	8.2	8.3	0.4	2	3.33	3.14	3.31	3.19	3.11	0	0	0
1.9	1.8	4.1	0	0.3	0.3	0.6	1.2	1.6	1.6	0.3	0.3	6.58	1.77	2.28	1.94	2.1	21.69	30.95	31.11
19.7	19.2	32.9	34.2	39.1	40	43.9	52.1	54.2	58.8	118.6	124.9	140.09	175.06	165.74	161.58	148.1	193.38	160.59	189.56
0.03	0.05	0.06	0.13	0.13	0.12	0.13	0.16	0.19	0.21	0.19	0.22	0.23	0.34	0.6	0.53	0.47	0.72	1.37	1.03

0	0	0	51.2	51.2	51.2	51.3	51.7	51.7	52	52.1	53.1	56.53	60.71	66.45	66.66	66.69	72.77	86.45	86.48
0	0	0	0.09	0.09	0.09	0.09	0.09	0.09	0.09	0.09	0.1	0.11	0.21	0.5	0.51	0.51	0.82	1.51	1.5
-20.6	-27.4	-34.1	-41.4	-56.2	-73	-81.7	-90.4	-88.6	-84.5	-68.9	-66	-92.04	-80.36	-107.1	-183	-289.73	-415.59	-610.33	-971.48
0	0	0.5	1.8	3.9	5.5	4.8	5.2	8.7	9.4	12.1	9.5	5.02	-4.28	5.43	-0.24	-3.85	4.48	5.57	-1.9
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-20.6	-27.4	-33.6	102.9	90.3	75.1	65.9	59.5	64.8	70.6	89	94.9	83.36	184.27	461.73	389	288.01	484.12	986.89	610.37
3.9	1.7	3.9	8.9	11.8	12.8	17.9	19.9	26.4	28.9	4.2	20.4	24.09	35.54	24.37	25.63	23.96	31.61	41.18	71.12
0	0	0	5.1	8.7	7.1	10.1	13.7	10.9	15.7	8.4	7.2	20.96	27.25	32.76	48.45	73.54	110.75	193.51	246.02
48.1	63.7	84.8	2	2.9	5.8	13.7	9.6	21.2	25.3	14.4	15.3	12.94	12.38	15.94	11.4	12.39	13.26	50.07	36.77
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.55	0	0	0	0	0
0	7.2	7.4	7.1	6.6	7.6	8.1	24.5	30	11.2	51.5	26.3	23.08	19.96	29.99	0	3.22	2.79	26.91	0
52	72.6	96.1	23.1	30	33.3	49.8	67.7	88.5	81.1	78.5	69.2	81.06	95.12	104.6	85.48	113.1	158.4	311.66	353.9
0	0	0	0	0	0	0.1	0	0	26.9	0	26.9	26.77	26.83	0	26.74	29.87	32.93	7.16	23.3
0	0	0	0	0	0.3	0.8	1.4	1.9	2.7	2.4	2.9	3.42	4	4.45	4.84	3.16	5.06	2.77	2.71
0	0	0	0	0	0	1.6	22.1	27.1	15.2	0	0	16.08	12.43	3.91	2.81	6.09	8.78	11.56	12.66
0	0	0	0	0	0.3	2.5	23.5	29	44.8	2.4	29.8	46.26	43.26	8.37	34.38	39.12	46.77	21.49	38.67
52	72.6	96.1	23.1	30	33.6	52.3	91.2	117.5	125.9	80.9	99	127.32	138.38	112.97	119.86	152.22	205.17	333.15	392.58
0.03	0.05	0.06	0.13	0.12	0.11	0.12	0.15	0.18	0.2	0.17	0.19	0.21	0.32	0.57	0.51	0.44	0.69	1.32	1

HUTCHMED (China) 브루토마진	HUTCHMED (China) 이익 마진	HUTCHMED (China) EBIT-마진	HUTCHMED (China) 이익 마진
2029e	54.12 %	0 %	0 %
2028e	54.12 %	24.74 %	0 %
2027e	54.12 %	16.59 %	17.27 %
2026e	54.12 %	4.93 %	11.99 %
2025e	54.12 %	-4.07 %	4.37 %
2024e	54.12 %	-20.21 %	-14.17 %
2023	54.12 %	2.19 %	12.03 %
2022	27.04 %	-95.61 %	-84.62 %
2021	27.49 %	-92.19 %	-54.66 %
2020	17.31 %	-86.27 %	-55.15 %
2019	21.84 %	-71.45 %	-51.75 %
2018	32.77 %	-43.27 %	-34.94 %
2017	27.11 %	-22.15 %	-11.08 %
2016	27.65 %	-21.61 %	5.41 %
2015	37.84 %	-5.48 %	-19.65 %
2014	32.61 %	-20.91 %	-37.58 %
2013	51.74 %	-2.17 %	12.83 %
2012	49.13 %	-0.67 %	1.84 %
2011	55.6 %	3.12 %	0.42 %
2010	59.41 %	-2.3 %	-5.13 %
2009	59.82 %	-5.05 %	-7.84 %
2008	58.39 %	-17.7 %	-20.46 %
2007	57.6 %	-14.9 %	-26.42 %
2006	59.3 %	-14.26 %	-16.7 %
2005	61.21 %	-16.36 %	-17.94 %
2004	66.29 %	-30.29 %	-38.29 %

	브루토마진	EBIT-마진	이익 마진
2004	66.29 %	-30.29 %	-38.29 %
2005	61.21 %	-16.36 %	-17.94 %
2006	59.3 %	-14.26 %	-16.7 %
2007	57.6 %	-14.9 %	-26.42 %
2008	58.39 %	-17.7 %	-20.46 %
2009	59.82 %	-5.05 %	-7.84 %
2010	59.41 %	-2.3 %	-5.13 %
2011	55.6 %	3.12 %	0.42 %
2012	49.13 %	-0.67 %	1.84 %
2013	51.74 %	-2.17 %	12.83 %
2014	32.61 %	-20.91 %	-37.58 %
2015	37.84 %	-5.48 %	-19.65 %
2016	27.65 %	-21.61 %	5.41 %
2017	27.11 %	-22.15 %	-11.08 %
2018	32.77 %	-43.27 %	-34.94 %
2019	21.84 %	-71.45 %	-51.75 %
2020	17.31 %	-86.27 %	-55.15 %
2021	27.49 %	-92.19 %	-54.66 %
2022	27.04 %	-95.61 %	-84.62 %
2023	54.12 %	2.19 %	12.03 %
2024e	54.12 %	-20.21 %	-14.17 %
2025e	54.12 %	-4.07 %	4.37 %
2026e	54.12 %	4.93 %	11.99 %
2027e	54.12 %	16.59 %	17.27 %
2028e	54.12 %	24.74 %	0 %
2029e	54.12 %	0 %	0 %

날짜	HUTCHMED (China) 주당 매출	HUTCHMED (China) EBIT 당 주식	HUTCHMED (China) 주당 이익
2029e	2 undefined	0 undefined	0 undefined
2028e	1.78 undefined	0 undefined	0 undefined
2027e	1.52 undefined	0 undefined	0.26 undefined
2026e	1.17 undefined	0 undefined	0.14 undefined
2025e	0.97 undefined	0 undefined	0.04 undefined
2024e	0.8 undefined	0 undefined	-0.11 undefined
2023	0.96 undefined	0.02 undefined	0.12 undefined
2022	0.5 undefined	-0.48 undefined	-0.43 undefined
2021	0.45 undefined	-0.41 undefined	-0.25 undefined
2020	0.33 undefined	-0.28 undefined	-0.18 undefined
2019	0.31 undefined	-0.22 undefined	-0.16 undefined
2018	0.32 undefined	-0.14 undefined	-0.11 undefined
2017	0.39 undefined	-0.09 undefined	-0.04 undefined
2016	0.36 undefined	-0.08 undefined	0.02 undefined
2015	0.33 undefined	-0.02 undefined	-0.06 undefined
2014	0.17 undefined	-0.03 undefined	-0.06 undefined
2013	0.09 undefined	-0 undefined	0.01 undefined
2012	0.37 undefined	-0 undefined	0.01 undefined
2011	0.32 undefined	0.01 undefined	0 undefined
2010	0.26 undefined	-0.01 undefined	-0.01 undefined
2009	0.22 undefined	-0.01 undefined	-0.02 undefined
2008	0.17 undefined	-0.03 undefined	-0.03 undefined
2007	0.13 undefined	-0.02 undefined	-0.03 undefined
2006	0.13 undefined	-0.02 undefined	-0.02 undefined
2005	0.07 undefined	-0.01 undefined	-0.01 undefined
2004	0.03 undefined	-0.01 undefined	-0.01 undefined

	주당 매출	EBIT 당 주식	주당 이익
2004	0.03 USD	-0.01 USD	-0.01 USD
2005	0.07 USD	-0.01 USD	-0.01 USD
2006	0.13 USD	-0.02 USD	-0.02 USD
2007	0.13 USD	-0.02 USD	-0.03 USD
2008	0.17 USD	-0.03 USD	-0.03 USD
2009	0.22 USD	-0.01 USD	-0.02 USD
2010	0.26 USD	-0.01 USD	-0.01 USD
2011	0.32 USD	0.01 USD	0 USD
2012	0.37 USD	-0 USD	0.01 USD
2013	0.09 USD	-0 USD	0.01 USD
2014	0.17 USD	-0.03 USD	-0.06 USD
2015	0.33 USD	-0.02 USD	-0.06 USD
2016	0.36 USD	-0.08 USD	0.02 USD
2017	0.39 USD	-0.09 USD	-0.04 USD
2018	0.32 USD	-0.14 USD	-0.11 USD
2019	0.31 USD	-0.22 USD	-0.16 USD
2020	0.33 USD	-0.28 USD	-0.18 USD
2021	0.45 USD	-0.41 USD	-0.25 USD
2022	0.5 USD	-0.48 USD	-0.43 USD
2023	0.96 USD	0.02 USD	0.12 USD
2024e	0.8 USD	0 USD	-0.11 USD
2025e	0.97 USD	0 USD	0.04 USD
2026e	1.17 USD	0 USD	0.14 USD
2027e	1.52 USD	0 USD	0.26 USD
2028e	1.78 USD	0 USD	0 USD
2029e	2 USD	0 USD	0 USD

	주식 수량
2004	512.1 백만 Aktien
2005	512.1 백만 Aktien
2006	457.1 백만 Aktien
2007	512.2 백만 Aktien
2008	512.3 백만 Aktien
2009	512.3 백만 Aktien
2010	515.3 백만 Aktien
2011	526.5 백만 Aktien
2012	526.5 백만 Aktien
2013	528.8 백만 Aktien
2014	525.63 백만 Aktien
2015	546.59 백만 Aktien
2016	599.71 백만 Aktien
2017	617.17 백만 Aktien
2018	664.26 백만 Aktien
2019	665.68 백만 Aktien
2020	697.93 백만 Aktien
2021	792.68 백만 Aktien
2022	847.14 백만 Aktien
2023	869.2 백만 Aktien
2024e	869.2 백만 Aktien
2025e	869.2 백만 Aktien
2026e	869.2 백만 Aktien
2027e	869.2 백만 Aktien
2028e	869.2 백만 Aktien
2029e	869.2 백만 Aktien

EPS-예상치	EPS-실제	보고 분기
-0.38	0.19 (149.86 %)	2023 Q2
-1.06	-0.26 (75.59 %)	2021 Q4
-0.77	-0.14 (81.88 %)	2021 Q2
-0.44	-0.11 (75.16 %)	2020 Q4
-0.55	-0.07 (87.18 %)	2020 Q2

%-지분	이름	주식	변경
4.88 %	Goldman Sachs Asset Management, L.P.	42,554,228	-2,077,483
4.69 %	The Carlyle Group	40,847,500	0
4.67 %	Capital Research Global Investors	40,718,761	-37,748,819
38.17 %	Hutchison Healthcare Holdings Ltd.	332,574,650	0
3.75 %	M&G Investment Management Ltd.	32,648,956	-17,705,520
2.89 %	Salata (Jean Eric)	25,173,775	-819,670
1.54 %	The Vanguard Group, Inc.	13,435,528	127,500
1.50 %	Capital International Investors	13,102,126	-67,208,804
1.38 %	GF Fund Management Co., Ltd.	12,008,500	4,544,500
1.04 %	Bosera Asset Management Co., Ltd.	9,080,000	2,265,000
1.02 %	Bank of China Investment Management Co., Ltd.	8,930,500	235,500
0.94 %	Su (Weiguo)	8,162,525	0
0.81 %	Norges Bank Investment Management (NBIM)	7,073,592	-1,261,641
0.80 %	Fidelity International	7,000,130	500
0.70 %	BlackRock Institutional Trust Company, N.A.	6,125,590	0
0.60 %	Penghua Fund Management Co., Ltd.	5,200,500	105,500
0.56 %	Fullgoal Fund Management Co., Ltd.	4,905,500	230,000
0.56 %	Huatai-PineBridge Fund Management Co., Ltd.	4,837,325	-227,175
0.49 %	E Fund Management Co. Ltd.	4,230,500	506,000
0.45 %	Chig Fung (Johnny Cheng)	3,933,925	0
0.44 %	Nuveen LLC	3,858,500	0
0.43 %	HuaAn Fund Management Co., Ltd.	3,705,000	760,000
0.42 %	Slater Investments Ltd.	3,659,480	0
0.38 %	China Asset Management Co., Ltd.	3,288,000	1,657,500
0.28 %	To (Simon)	2,466,185	0
0.26 %	FIL Investment Management (Hong Kong) Limited	2,282,015	-6,464
0.24 %	Harvest Fund Management Co., Ltd.	2,132,000	2,073,000
0.20 %	ICBC Credit Suisse Asset Management Co. Ltd.	1,780,500	-996,500
0.20 %	BlackRock Advisors (UK) Limited	1,775,555	7,500
0.14 %	Shih (Edith)	1,200,000	0
0.13 %	BlackRock Investment Management (UK) Ltd.	1,152,730	0
0.12 %	China Southern Asset Management Co. Ltd.	1,020,000	793,000
0.12 %	China Universal Asset Management Co., Ltd.	1,018,000	428,500
0.11 %	Schroder Investment Management Ltd. (SIM)	940,489	0
0.10 %	Charles Schwab Investment Management, Inc.	869,443	7,735
0.08 %	State Street Global Advisors (UK) Ltd.	727,676	0
0.08 %	Zhong Ou Asset Management Co., Ltd.	725,500	668,500
0.07 %	APG Asset Management N.V.	622,903	-114,207
0.07 %	China Asset Management (Hong Kong) Limited	613,840	-29,500
0.07 %	Essence Fund Management Co., Ltd.	572,500	551,500
0.06 %	Maxwealth Fund Management Co., Ltd.	555,090	-248,910
0.06 %	Nikko Asset Management Asia Limited	492,000	19,000
0.06 %	Amundi (UK)	484,000	90,500
0.05 %	Morgan Stanley Investment Management (China) Company Limited.	475,500	80,000
0.05 %	DB Asset Management Co Ltd.	393,000	0
0.04 %	Matthews International Capital Management, L.L.C.	380,000	0
0.04 %	Mellon Investments Corporation	371,000	-111,000
0.04 %	Wanjia Asset Management Co., Ltd.	367,000	367,000
0.04 %	Mirae Asset Global Investments (Hong Kong) Limited	349,766	-2,000
0.04 %	Guotai Asset Management Co., Ltd.	325,005	63,005
0.04 %	Legal & General Investment Management Ltd.	322,473	0
0.03 %	HSBC Global Asset Management (UK) Limited	292,759	-146
0.03 %	Macquarie Investment Management	271,000	0
0.03 %	Yinhua Fund Management Co., Ltd.	240,000	-443,000
0.03 %	Geode Capital Management, L.L.C.	234,820	0
0.03 %	BlackRock Financial Management, Inc.	234,500	47,500
0.02 %	Royal London Asset Management Ltd.	202,000	0
0.02 %	Nomura Asset Management Taiwan Limited	178,479	178,479
0.02 %	Eldar (Dan)	150,660	0
0.02 %	BOCI-Prudential Asset Management Ltd.	147,500	0
0.02 %	River Global Investors LLP	140,513	-5,787
0.02 %	Mok (Tony)	136,705	0
0.02 %	Tianhong Asset Management Co., Ltd.	135,000	35,500
0.02 %	Handelsbanken Kapitalförvaltning AB	134,000	17,000
0.01 %	KLP Fondsforvaltning AS	123,000	0
0.01 %	UBS Asset Management (UK) Ltd.	122,630	0
0.01 %	T. Rowe Price International Ltd	120,528	-8,224
0.01 %	Hanwha Asset Management Co., Ltd.	119,000	76,000
0.01 %	State Street Global Advisors (US)	117,653	34
0.01 %	Tibet Eastmoney Fund Management Co., Ltd.	116,000	-10,500
0.01 %	Western Leadbank Fund Management Co., Ltd.	113,500	22,500
0.01 %	Mirae Asset Global Investments Co., Ltd.	113,012	112,072
0.01 %	Zhong Hai Fund Management Co., Ltd.	111,823	21,618
0.01 %	Ferrante (Karen Jean)	109,805	0
0.01 %	Carter (Paul)	108,925	0
0.01 %	Hwabao WP Fund Management Co., Ltd.	106,500	66,000
0.01 %	Jack (Graeme Allan)	101,695	0
0.01 %	Apo Asset Management GmbH	96,500	-40,000
0.01 %	BlackRock Asset Management North Asia Limited	83,500	0
0.01 %	Amundi Asset Management, SAS	80,329	2,923
0.01 %	AFH Wealth Management	76,070	0
0.01 %	Great Wall Fund Management Co., Ltd.	70,000	-30,000
0.01 %	Numeric Investors LLC	68,529	176
0.01 %	Changjiang Securities (Shanghai) Asset Mgmt. Co., Ltd.	60,000	60,000
0.01 %	Xinyuan Asset Management Co., Ltd.	56,000	56,000
0.01 %	Lion Fund Management Co., Ltd.	54,000	38,500
0.01 %	Vanguard Global Advisers LLC	51,500	500
0.01 %	ReAssure Limited	50,859	-3,467
0.01 %	Xinghua Fund Management Co., Ltd.	50,000	50,000
0.01 %	Amundi SGR SpA	49,000	0
0.01 %	JPMorgan Asset Management (China) Company Limited.	46,500	46,500
0.01 %	Allianz Global Investors Asia Pacific Limited	45,500	45,500
0.01 %	Ping An Fund Management Company Limited	45,000	10,000
0.00 %	Barclays Wealth	40,181	-3,260
0.00 %	Scottish Friendly Asset Managers Limited	39,158	-3,244
0.00 %	Hang Seng Investment Management Ltd.	39,000	36,000
0.00 %	Phillip Capital Management (S) Ltd.	34,957	723
0.00 %	Renaissance Capital LLC	31,000	2,000
0.00 %	PGGM Vermogensbeheer B.V.	29,152	-208,113
0.00 %	Nykredit Bank AS	24,000	0

What values and corporate philosophy does HUTCHMED (China) represent?

Hutchison China MediTech Ltd (Chi-Med) represents a strong corporate philosophy focused on innovation, patient-centricity, and scientific excellence. The company strives to improve healthcare outcomes through its cutting-edge therapies and medicines. Hutchison China MediTech Ltd values transparency, integrity, and collaboration, fostering partnerships with healthcare professionals, patients, and the broader community. With a commitment to research and development, Chi-Med aims to address unmet medical needs and provide effective solutions for patients. By continuously pushing boundaries and leveraging its expertise, Hutchison China MediTech Ltd strives to deliver high-quality healthcare products, contributing to the advancement of the medical industry.

In which countries and regions is HUTCHMED (China) primarily present?

Hutchison China MediTech Ltd, commonly known as Chi-Med, primarily operates in China and the United States. As a multinational biopharmaceutical company, Chi-Med focuses on discovering, developing, and commercializing innovative medicines. With its headquarters in Hong Kong and clinical development operations in mainland China, Chi-Med maintains a significant presence in these regions. Additionally, the company has expanded its reach to the United States, establishing a presence in order to access global markets, collaborate with key stakeholders, and enhance its international footprint. Chi-Med's commitment to growth and collaboration across these countries and regions strengthens its position in the global healthcare market.

What significant milestones has the company HUTCHMED (China) achieved?

Hutchison China MediTech Ltd, also known as Chi-Med, has achieved several significant milestones. One notable achievement is the successful development and commercialization of innovative oncology and immunology drugs. The company has obtained approvals from global regulatory authorities for multiple drugs in various indications. Additionally, Chi-Med has entered into strategic partnerships with renowned international pharmaceutical companies for the co-development and commercialization of certain products. Moreover, the company has expanded its operations globally, establishing subsidiaries and research centers in multiple countries. These achievements demonstrate Hutchison China MediTech Ltd's commitment to advancing healthcare through groundbreaking research and development.

What is the history and background of the company HUTCHMED (China)?

Hutchison China MediTech Ltd (Chi-Med) is a leading biopharmaceutical company based in China. Founded in 2000, the company focuses on researching, developing, and commercializing innovative therapies in oncology and immunology. Chi-Med has a strong track record in discovering and developing novel, targeted therapies, with a particular emphasis on precision medicines. The company has successfully launched multiple drugs in China and is expanding its global presence. Chi-Med's commitment to transforming healthcare has earned it recognition and numerous awards within the industry. With a dedicated team and breakthrough innovations, Hutchison China MediTech Ltd continues to make significant contributions to the field of biopharmaceuticals.

Who are the main competitors of HUTCHMED (China) in the market?

Some of the main competitors of Hutchison China MediTech Ltd in the market include BeiGene Ltd, Simcere Pharmaceutical Group, and Zai Lab Ltd.

In which industries is HUTCHMED (China) primarily active?

Hutchison China MediTech Ltd, also known as Chi-Med, is primarily active in the biopharmaceutical industry.

What is the business model of HUTCHMED (China)?

Hutchison China MediTech Ltd, also known as Chi-Med, operates under a diversified business model in the healthcare sector. The company focuses on research and development of innovative medicines, primarily in oncology and immunology therapeutic areas. Chi-Med's business model encompasses developing both internally discovered and externally sourced products, and commercializing them through strategic partnerships and independent commercialization efforts. With a strong pipeline of potential drug candidates and expertise in precision medicine, Chi-Med aims to bring novel therapies to patients and improve healthcare outcomes. By leveraging its integrated platform, Chi-Med strives to become a leading biopharmaceutical company in China and globally.

HUTCHMED (China) 2024의 P/E 비율은 얼마입니까?

HUTCHMED (China)의 P/E 비율은 -3.13입니다.

HUTCHMED (China) 2024의 KUV는 얼마입니까?

HUTCHMED (China)의 P/S 비율은 0.44입니다.

HUTCHMED (China)의 AlleAktien 품질 점수는 얼마인가요?

HUTCHMED (China)에 대한 AlleAktien 품질 점수는 3/10입니다.

HUTCHMED (China) 2024의 매출은 얼마인가요?

예상되는 HUTCHMED (China) 매출은 697.44 백만 USD입니다.

HUTCHMED (China) 2024의 이익은 얼마인가요?

예상되는 HUTCHMED (China) 이익은 -98.85 백만 USD입니다.

HUTCHMED (China)은 무엇을 하나요?

Hutchison China MediTech Limited (Chi-Med) is a pharmaceutical company that focuses on developing, manufacturing, and marketing innovative drugs in China and globally. The company has three main business areas: Innovative oncology products, consumer health, and research and development platforms.

HUTCHMED (China) 배당금은 얼마입니까?

HUTCHMED (China)은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

HUTCHMED (China)이 얼마나 자주 배당을 지급하나요?

HUTCHMED (China)의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

HUTCHMED (China) ISIN이 무엇입니까?

HUTCHMED (China)의 ISIN은 KYG4672N1198입니다.

HUTCHMED (China) WKN은 무엇인가요?

HUTCHMED (China)의 WKN은 A2PJ5B입니다.

HUTCHMED (China) 티커는 무엇인가요?

HUTCHMED (China)의 티커는 13.HK입니다.

HUTCHMED (China)이 얼마만큼의 배당금을 지급합니까?

지난 12개월 동안 HUTCHMED (China)은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 HUTCHMED (China)은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

HUTCHMED (China)의 배당 수익률은 얼마입니까?

HUTCHMED (China)의 현재 배당 수익률은 입니다.

HUTCHMED (China)의 배당금은 언제 지급되나요?

HUTCHMED (China)은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

HUTCHMED (China)의 배당금은 얼마나 안전한가요?

HUTCHMED (China)은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

HUTCHMED (China)의 배당금은 얼마입니까?

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

HUTCHMED (China)이(가) 속해 있는 섹터는 어디인가요?

HUTCHMED (China)은 '건강' 섹터에 속합니다.

Wann musste ich die Aktien von HUTCHMED (China) kaufen, um die vorherige Dividende zu erhalten?

HUTCHMED (China)의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

HUTCHMED (China)의 마지막 배당금 지급일은 언제였습니까?

마지막 배당금 지급일은 입니다.

HUTCHMED (China)의 2023년도 배당금은 얼마였습니까?

2023년에 HUTCHMED (China)는 0 USD를 배당금으로 지급했습니다.

HUTCHMED (China)는 어떤 화폐로 배당금을 지급하나요?

HUTCHMED (China)의 배당금은 USD에 지급됩니다.

Scope 1 - 직접 방출	5,587
스코프 2 - 구매한 에너지로부터의 간접적인 배출	14,519
Scope 3 - 가치 창출 체인 내의 간접 배출	442
총 CO₂ 배출량	20,106
CO₂ 감소 전략	✅
석탄 에너지	❌
원자력	❌
동물 실험	✅
펠츠 & 레더	—
살충제	—
팜 오일	—
담배	❌
유전자 변형 생물체	❌
기후 개념	—
지속 가능한 임업	—
재활용 규정	✅
환경 친화적인 포장	❌
위험물질	✅
연료 소비량과 효율성	❌
물 사용량 및 효율성	✅

여성 직원 비율	51
관리 직위에서의 여성 비율	—
아시아 직원 비율	—
아시아 경영진 비율	—
히스패닉/라티노 직원 비율	—
히스패닉/라티노 관리 부문 지분	—
흑인 직원 비율	—
블랙 매니지먼트 지분	—
흰색 종업원의 비율	—
화이트 매니지먼트 지분	—
성인 콘텐츠	❌
알코올	❌
무기	—
총기	❌
도박	❌
군사 계약	❌
인권 개념	❌
개인정보 보호 정책	—
작업 및 건강 보호	✅
카톨릭	✅

환경 보고	✅
이해관계자 참여	✅
콜백 정책	❌
카르텔법	❌

증권거래소	HUTCHMED (China) 티커
뒤셀도르프	H7T2.DU
프랑크푸르트	H7T2.F
HKSE	0013.HK
LONDON	HCM.L
LONDON STOCK EXCHANGE	HCM.L
뮌헨	H7T2.MU
PNK	HMDCF

HUTCHMED (China) 티커	HUTCHMED (China) FIGI
HCM:LN	BBG000P4SQF9
H7T2:GR	BBG000PLPFJ4
H7T2:GF	BBG000PLPFV0
H7T2:GD	BBG000PLPG75
H7T2:GS	BBG000PLPGQ4
H7T2:GM	BBG000PLPJ06
H7T2:GB	BBG000PLPJ97
HCM1:EO	BBG000PY49V9
HCM1:XL	BBG000PY4GC4
HCM1:E1	BBG000PY4JN6
HCM1:XT	BBG000PY4K71
HCM1:XW	BBG000PY4KD4
HCM1:EU	BBG000QHVXT5
HCM1EUR:EO	BBG000QYSTW7
HCM1EUR:E1	BBG000QYT1T1
HCM1EUR:XT	BBG000QYT237
HCM1EUR:XW	BBG000QYT282
HCM1:PZ	BBG000VY2PV8
HCM1:XV	BBG005918GG5
HCM1EUR:XV	BBG00591BJH4
HCML:B3	BBG006T7M0K2
HCML:L3	BBG006TBRKG9
HCM1EUR:EU	BBG008FK6GK7
HCML:PO	BBG008GZQD00
HCM1:XX	BBG00JN763H6
HCM1EUR:XX	BBG00JN78598
HCM1USD:XS	BBG00KSNYRD3
HCM1USD:XH	BBG00KSNYRH9
HCM1USD:XF	BBG00KSNYRK5
HCM1USD:XE	BBG00KSNYRM3
HCM1USD:XJ	BBG00KSNYRN2
HCM1USD:XL	BBG00KSNYRP0
HCM1USD:XG	BBG00KSNYRQ9
HCM1USD:XO	BBG00KSNYRR8
HCM1USD:XA	BBG00KSNYRW2
HCM1USD:E1	BBG00KSNYRX1
HCM1USD:XT	BBG00KSNYRY0
HCM1USD:XW	BBG00KSNYRZ9
HCM1USD:XU	BBG00KSNYS05
HCM1USD:XV	BBG00KSNYS14
HCM1USD:XM	BBG00KSNYS23
HCM1USD:XQ	BBG00KSNYS41
HCM1USD:XX	BBG00KSNYS50
HCM1USD:XZ	BBG00KSNYS69
HCM1USD:EU	BBG00KSNYS96
13:HK	BBG011J3CPR1
H7T2:GZ	BBG011K1Y2Q1
H7T2:TH	BBG011MNGCK5
H7T2:QT	BBG011N2NX35
13:H2	BBG012DZLJ34
13:H1	BBG012N30Z59
HCM1HKD:XH	BBG0134LM3V6
HCM1HKD:XF	BBG0134LM3Y3
HCM1HKD:XE	BBG0134LM408
HCM1HKD:XL	BBG0134LM426
HCM1HKD:XG	BBG0134LM435
HCM1HKD:XO	BBG0134LM444
HCM1HKD:XA	BBG0134LM480
HCM1HKD:XT	BBG0134LM4C5
HCM1HKD:XW	BBG0134LM4D4
HCM1HKD:XU	BBG0134LM4F2
HCM1HKD:XV	BBG0134LM4H0
HCM1HKD:XM	BBG0134LM4K6
HCM1HKD:EU	BBG0134LM596
H7T2:LA	BBG018H8JVN1
H7T2:LU	BBG018J25Y24
HMDCF:US	BBG0195R5DJ0
HMDCF:PQ	BBG0195R5DY3
HMDCF:UV	BBG0195R5DZ2
HCML:TQ	BBG01HBKZX03

2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
-13	-7	-6	-8	-15	-16	-7	-5	1	3	7	-4	10	14	-22	-71	-103	-115	-167	-360	101
1	1	2	2	3	4	4	4	4	4	0	1	2	2	2	3	4	6	7	8	8
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-2	-6	-9	0	-1	-3	13	-21	-6	11	4	24	-3	33	41	42	44	115	82	100	114
4	2	0	2	6	2	0	2	5	-3	-7	-13	-18	-60	-29	-7	-26	-68	-126	-17	-4
0	0	0	0	0	0	0	0	0	1,000	1,000	1,000	1,000	1,000	0	0	0	0	0	0	0
0	0	0	0	0	1	1	2	3	3	1	0	0	2	3	3	3	5	5	18	3
-9	-10	-13	-3	-7	-13	11	-19	5	15	5	8	-9	-9	-8	-32	-80	-62	-204	-268	219
-9	-3	-1	-2	-7	-3	-7	-8	-6	-12	-2	-3	-3	-4	-5	-6	-8	-19	-16	-36	-32
-9	-3	-27	-2	-7	-3	-7	-11	-5	-11	-2	-15	8	-33	-260	43	119	-125	-306	296	-291
0	0	-26	0	0	0	0	-2	0	0	0	-11	12	-29	-255	50	127	-105	-289	333	-258
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	7	0	0	0	0	0	-10	0	-18	13	-5	-3	-4	-16	-4	0	0	0	-9	61
0	0	0	68	0	0	0	20	0	-4	0	2	0	109	300	-1	0	306	690	-47	-3
20	26	30	70	-2	1	0	33	7	4	13	0	-5	92	273	-8	-1	296	650	-82	48
20	19	30	2	-1	0	-1	23	8	27	0	1	-1	-13	-10	-2	-1	-9	-39	-25	-9
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	13	-10	65	-17	-15	3	3	8	8	16	-7	-7	47	5	0	35	114	141	-64	-29
-19.07	-13.11	-15.27	-5.71	-14.9	-16.45	4.41	-28.3	-0.96	3.58	2.53	4.63	-12.71	-13.9	-13.96	-39.21	-89.48	-81.65	-220.98	-305.26	186.65
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e	2027e	2028e	2029e
0.01	0.02	0.04	0.06	0.07	0.09	0.11	0.13	0.17	0.2	0.05	0.09	0.18	0.22	0.24	0.21	0.2	0.23	0.36	0.43	0.84	0.7	0.85	1.02	1.33	1.55	1.74
-	30.77	117.65	54.05	14.04	33.85	27.59	20.72	23.88	17.47	-76.41	89.13	104.60	21.35	11.57	-11.20	-4.67	11.27	56.83	19.66	96.48	-16.73	21.52	20.31	30.32	16.72	12.52
61.54	64.71	62.16	59.65	56.92	57.47	59.46	58.96	55.42	49.23	50.00	32.18	37.64	27.31	26.97	32.71	21.57	17.18	27.25	27.00	54.12	-	-	-	-	-	-
8	11	23	34	37	50	66	79	92	96	23	28	67	59	65	70	44	39	97	115	453	0	0	0	0	0	0
-9	-5	-6	-8	-9	-15	-5	-3	5	-1	-1	-18	-9	-46	-53	-92	-146	-196	-328	-407	18	-140	-34	50	220	383	0
-69.23	-29.41	-16.22	-14.04	-13.85	-17.24	-4.50	-2.24	3.01	-0.51	-2.17	-20.69	-5.06	-21.30	-21.99	-42.99	-71.57	-86.34	-92.13	-95.54	2.15	-20.09	-4.01	4.91	16.57	24.71	-
-10	-6	-6	-9	-17	-17	-8	-6	0	3	5	-32	-35	11	-26	-74	-106	-125	-194	-360	100	-98	37	122	229	0	0
-	-40.00	-	50.00	88.89	-	-52.94	-25.00	-	-	66.67	-740.00	9.38	-131.43	-336.36	184.62	43.24	17.92	55.20	85.57	-127.78	-198.00	-137.76	229.73	87.70	-	-
512.1	512.1	512.1	457.1	512.2	512.3	512.3	515.3	526.5	526.5	528.8	525.63	546.59	599.71	617.17	664.26	665.68	697.93	792.68	847.14	869.2	0	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

한 눈에 저평가된 주식을 인식하세요 fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

가격

가격

티커13.HK

ISINKYG4672N1198

WKNA2PJ5B

HUTCHMED (China) 주식 가격

가격

개요

인트라데이 기능

총 수익률 및 상대 가격 변동

해석 및 투자

HUTCHMED (China) 주가 이력

HUTCHMED (China) 주식 매출, EBIT, 이익 KYG4672N1198 · A2PJ5B

매출, 이익 & EBIT

매출, EBIT, 소득 이해하기

연간 분석 및 비교

투자 기대치 활용

투자 통찰력

HUTCHMED (China) 매출, 이익 및 EBIT 역사

HUTCHMED (China) 주식 지표

손익계산서

매출 성장

총 이익률

EBIT와 EBIT 마진

수입과 성장

발행 주식

연간 비교의 해석

기대치와 예측

재무 상태표

재무 상태표 이해

자산

부채

자본

년대비 분석

데이터 해석

HUTCHMED (China) 주식 마진 KYG4672N1198 · A2PJ5B

마진

매출 총이익률 이해

EBIT 마진 분석

매출 마진에 대한 인사이트

기대치 해석

비교 분석

HUTCHMED (China) 마진 역사

HUTCHMED (China) 주식 매출, EBIT, 주당 순이익 KYG4672N1198 · A2PJ5B

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

HUTCHMED (China) 매출, 이익 및 EBIT 주당 역사

HUTCHMED (China) 주식 및 주식 분석

HUTCHMED (China) Fair Value에 따른 평가

Fair Value

Fair Value 이해하기

수익 기반 Fair Value

매출 기반 Fair Value

배당 기반 Fair Value

기대치와 예측

비교 분석

HUTCHMED (China) 역사적인 P/E, EBIT 및 P/S에 따른 평가

HUTCHMED (China) 주식 수량 KYG4672N1198 · A2PJ5B

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

HUTCHMED (China) 수익 예상

HUTCHMED (China) 수익 놀라움

Eulerpool ESG Scorecard© HUTCHMED (China) 주식을 위해

Eulerpool World ESG Rating (EESG©)

63/ 100

🌱 Environment

👫 Social

🏛️ Governance

환경

소셜 (사회적)

지배구조 (기업 경영)

HUTCHMED (China) 주식 주주 구조

HUTCHMED (China) 임원진 및 경영진

한 눈에 저평가된 주식을 인식하세요
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

티커
13.HK

ISIN
KYG4672N1198

WKN
A2PJ5B